https://www.selleckchem.com/pr....oducts/Cisplatin.htm
Introduction The treatment of rheumatoid arthritis (RA), a chronic, systemic, autoimmune disease, has been greatly advanced by the introduction of biologic disease-modifying antirheumatic drugs (DMARDs); however, many patients still fail to achieve disease remission. Peficitinib, an orally bioavailable inhibitor of the Janus kinase (JAK) receptor family, was approved in Japan in 2019 and Korea in 2020 for the treatment of RA.Areas covered This review provides an overview of JAK inhibitors currently marketed or in development; the phar
Like
Comment
Share
